Chester County News and Community Website
WASHINGTON, D.C. — The U.S. Food and Drug Administration recently expanded the approval of the COVID-19 treatment Veklury (remdesivir) to include pediatric patients 28 days of age and older weighing …
FDA Approves First COVID-19 Treatment for Young Children Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration has issued an emergency use authorization (EUA) for Merck’s molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive …
FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults Read More WASHINGTON, D.C. — The Biden Administration announced it recently secured 10 million treatment courses of Pfizer’s promising COVID-19 oral antiviral drug, contingent on emergency use authorization (EUA) or approval from …
Federal Government Secures 10 Million Courses of Pfizer’s COVID-19 Oral Antiviral Medicine Read More
RADNOR, PA — NRx Pharmaceuticals (NASDAQ: NRXP) provided a recent safety update on ZYESAMI® (aviptadil), which is being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the …
NRx Pharmaceuticals Announces Favorable, New Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with COVID-19 Read More
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that it recently submitted to bioRxiv a preprint of a manuscript regarding preclinical research of the company’s SARS-CoV-2 antibody cocktail, IMM-BCP-01. The …
Immunome Announces Submission for Publication of Pre-clinical Research for SARS-CoV-2 Treatment and Prophylaxis Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration announced an upcoming meeting of its Antimicrobial Drugs Advisory Committee (AMDAC) to discuss Merck and Ridgeback’s request for an emergency use …
FDA to Hold Advisory Committee Meeting to Discuss Merck and Ridgeback’s EUA Application for COVID-19 Oral Treatment Read More RADNOR, PA — NRx Pharmaceuticals (NRx) (NASDAQ: NRXP) recently provided a safety update on ZYESAMI™ (aviptadil) which is being tested in the ACTIV-3 Critical Care Phase 3 study sponsored by the National …
NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI in NIH Sponsored ACTIV-3 Critical Care Study Read More
DOYLESTOWN, PA — Evrys Bio has been awarded a $34.3 million contract from the Department of Defense (DOD) to develop a drug, simultaneously effective against multiple high-risk viral agents.
Evrys Bio Awarded $34 Million from Department of Defense Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced it has received authorization from the U.S. Food and Drug Administration to proceed with its Investigational New Drug (IND) application for …
Arbutus Receives Authorization to Proceed with an Investigational New Drug Application Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration recently issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy sotrovimab for the treatment of mild-to-moderate COVID-19 in adults …
FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19 Read More